PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $927,917 | +10.2% | 30,245 | +44.0% | 0.00% | 0.0% |
| Q2 2023 | $841,791 | +60.3% | 21,008 | +112.7% | 0.00% | – |
| Q3 2022 | $525,000 | -56.8% | 9,876 | -43.1% | 0.00% | -100.0% |
| Q1 2021 | $1,216,000 | +17.1% | 17,345 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,038,000 | -23.1% | 17,345 | -22.7% | 0.00% | 0.0% |
| Q3 2020 | $1,349,000 | +4.6% | 22,442 | -8.7% | 0.00% | 0.0% |
| Q2 2020 | $1,290,000 | -20.4% | 24,591 | -49.1% | 0.00% | -50.0% |
| Q1 2020 | $1,621,000 | -2.5% | 48,358 | +31.8% | 0.00% | 0.0% |
| Q4 2019 | $1,662,000 | -53.5% | 36,696 | -60.9% | 0.00% | -50.0% |
| Q3 2019 | $3,573,000 | -9.6% | 93,844 | +3.2% | 0.00% | 0.0% |
| Q2 2019 | $3,954,000 | +18.4% | 90,918 | +3.6% | 0.00% | +33.3% |
| Q1 2019 | $3,339,000 | +27.6% | 87,723 | +53.0% | 0.00% | 0.0% |
| Q4 2017 | $2,617,000 | +37.2% | 57,322 | +12.9% | 0.00% | +50.0% |
| Q3 2017 | $1,907,000 | -20.7% | 50,794 | +0.7% | 0.00% | 0.0% |
| Q2 2017 | $2,405,000 | +0.5% | 50,424 | -3.9% | 0.00% | 0.0% |
| Q1 2017 | $2,392,000 | +38.4% | 52,465 | -1.9% | 0.00% | 0.0% |
| Q4 2016 | $1,728,000 | -17.8% | 53,494 | -12.9% | 0.00% | 0.0% |
| Q3 2016 | $2,101,000 | -6.2% | 61,385 | -7.5% | 0.00% | -33.3% |
| Q2 2016 | $2,239,000 | -36.1% | 66,391 | +0.3% | 0.00% | -25.0% |
| Q1 2016 | $3,506,000 | -31.3% | 66,185 | -0.4% | 0.00% | -33.3% |
| Q4 2015 | $5,102,000 | +201.2% | 66,438 | +61.2% | 0.01% | +200.0% |
| Q3 2015 | $1,694,000 | -96.5% | 41,223 | -94.0% | 0.00% | -96.4% |
| Q2 2015 | $48,662,000 | +28.2% | 688,092 | +61.1% | 0.06% | +31.0% |
| Q1 2015 | $37,961,000 | +27.8% | 427,244 | +27.5% | 0.04% | +23.5% |
| Q4 2014 | $29,710,000 | +1009.8% | 335,095 | +1113.2% | 0.03% | +1033.3% |
| Q3 2014 | $2,677,000 | +3.0% | 27,620 | -2.3% | 0.00% | 0.0% |
| Q2 2014 | $2,598,000 | +36.4% | 28,282 | +3.9% | 0.00% | +50.0% |
| Q1 2014 | $1,904,000 | +13.3% | 27,210 | -6.9% | 0.00% | 0.0% |
| Q4 2013 | $1,680,000 | +19.1% | 29,220 | -0.3% | 0.00% | 0.0% |
| Q3 2013 | $1,410,000 | +79.6% | 29,310 | +6.4% | 0.00% | +100.0% |
| Q2 2013 | $785,000 | – | 27,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |